Arrowhead Pharmaceuticals Valuation
Is ARWR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Sales gegen Gleichaltrige
Price-To-Sales gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of ARWR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: ARWR ($26.19) wird unter unserer Schätzung des Fair Value ($26.9) gehandelt.
Deutlich unter dem Marktwert: ARWR unter dem beizulegenden Zeitwert gehandelt wird, jedoch nicht um einen signifikanten Betrag.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ARWR?
Other financial metrics that can be useful for relative valuation.
| What is ARWR's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$3.50b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 20.3x |
| Enterprise Value/EBITDA | -12.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ARWR's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 15.4x | ||
INSM Insmed | 12.8x | 34.6% | US$4.0b |
ALVO Alvotech | 34.1x | 43.1% | US$3.5b |
FOLD Amicus Therapeutics | 8.4x | 21.9% | US$3.5b |
HALO Halozyme Therapeutics | 6.2x | 13.5% | US$5.2b |
ARWR Arrowhead Pharmaceuticals | 17.9x | 32.9% | US$3.5b |
Price-To-Sales gegen Gleichaltrige: ARWR ist auf der Grundlage des Price-To-Sales Verhältnisses (19.3x) im Vergleich zum Durchschnitt der Vergleichsgruppe (7.4x) teuer.
Price to Earnings Ratio vs Industry
How does ARWR's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales gegen Industrie: ARWR ist teuer, wenn man sein Price-To-Sales Verhältnis (11x) mit dem US Biotechs Branchendurchschnitt (10.9x) vergleicht.
Price to Sales Ratio vs Fair Ratio
What is ARWR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 17.9x |
| Fair PS Ratio | 15.5x |
PM vs. Fair Ratio: ARWR ist teuer auf der Grundlage des Verhältnisses Price-To-Sales (11x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Sales (10.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$26.19 | US$55.15 +110.6% | 33.3% | US$90.00 | US$28.00 | n/a | 13 |
| Mar ’25 | US$36.08 | US$55.15 +52.9% | 33.3% | US$90.00 | US$28.00 | n/a | 13 |
| Feb ’25 | US$32.19 | US$55.46 +72.3% | 36.0% | US$90.00 | US$27.00 | n/a | 13 |
| Jan ’25 | US$30.60 | US$53.29 +74.1% | 39.6% | US$90.00 | US$24.00 | n/a | 14 |
| Dec ’24 | US$23.17 | US$53.83 +132.3% | 38.0% | US$90.00 | US$24.00 | n/a | 12 |
| Nov ’24 | US$25.79 | US$55.93 +116.9% | 34.7% | US$90.00 | US$26.00 | n/a | 14 |
| Oct ’24 | US$26.87 | US$56.71 +111.1% | 33.9% | US$90.00 | US$27.00 | n/a | 14 |
| Sep ’24 | US$27.96 | US$58.54 +109.4% | 32.0% | US$90.00 | US$27.00 | n/a | 13 |
| Aug ’24 | US$33.68 | US$62.15 +84.5% | 28.1% | US$90.00 | US$27.00 | n/a | 13 |
| Jul ’24 | US$35.66 | US$61.77 +73.2% | 28.4% | US$90.00 | US$27.00 | n/a | 13 |
| Jun ’24 | US$34.67 | US$62.07 +79.0% | 28.0% | US$90.00 | US$27.00 | n/a | 14 |
| May ’24 | US$35.72 | US$61.14 +71.2% | 28.8% | US$90.00 | US$27.00 | n/a | 14 |
| Apr ’24 | US$25.40 | US$61.00 +140.2% | 33.2% | US$90.00 | US$21.00 | US$28.24 | 14 |
| Mar ’24 | US$32.66 | US$63.62 +94.8% | 29.2% | US$90.00 | US$21.00 | US$36.08 | 13 |
| Feb ’24 | US$35.29 | US$65.38 +85.3% | 29.0% | US$90.00 | US$22.00 | US$32.19 | 13 |
| Jan ’24 | US$40.56 | US$69.69 +71.8% | 26.7% | US$92.00 | US$31.00 | US$30.60 | 13 |
| Dec ’23 | US$32.02 | US$71.23 +122.5% | 29.4% | US$110.00 | US$31.00 | US$23.17 | 13 |
| Nov ’23 | US$35.52 | US$73.50 +106.9% | 29.1% | US$110.00 | US$32.00 | US$25.79 | 12 |
| Oct ’23 | US$33.05 | US$74.46 +125.3% | 26.3% | US$110.00 | US$39.00 | US$26.87 | 13 |
| Sep ’23 | US$41.29 | US$77.25 +87.1% | 22.9% | US$110.00 | US$39.00 | US$27.96 | 12 |
| Aug ’23 | US$41.77 | US$76.83 +83.9% | 25.5% | US$110.00 | US$35.00 | US$33.68 | 12 |
| Jul ’23 | US$35.96 | US$77.17 +114.6% | 25.0% | US$110.00 | US$35.00 | US$35.66 | 12 |
| Jun ’23 | US$33.05 | US$78.08 +136.3% | 22.4% | US$100.00 | US$35.00 | US$34.67 | 12 |
| May ’23 | US$41.11 | US$86.25 +109.8% | 20.7% | US$106.00 | US$36.00 | US$35.72 | 12 |
| Apr ’23 | US$49.20 | US$86.25 +75.3% | 20.7% | US$106.00 | US$36.00 | US$25.40 | 12 |
Analysten-Prognose: Das Kursziel liegt um mehr als 20% über dem aktuellen Aktienkurs, aber die Analysten liegen nicht in einem statistisch sicheren Bereich der Übereinstimmung.